Strong Q4 and record order book – despite a challenging environment, INDUS will be able to increase revenue and adjusted EBITA in 2026
 
Revenue (€1.735 billion; +0.8%) and adjusted EBITA (€147.8 million; -3.8%) for 2025 had already been provisionally reported. EAT (€69.8 million; +28%) and EPS (2.77; +34%) increased disproportionately. However, this success was aided by one-off effects that had a positive impact on the tax rate. The overall economic environment in 2026 remains challenging and difficult to predict (war in Iran). We expect INDUS to succeed in expanding revenue in 2026 and also increasing adjusted EBITA. Q1, however, could be weaker than the same quarter last year. Based on our estimates, the INDUS share remains attractively valued with a 2026 P/E ratio of 9.4 and a dividend yield of just under 5%.   
 
All three segments are expected to contribute to revenue growth in 2026. In the Infrastructure segment, INDUS anticipates a moderate rise in revenue, accompanied by a sharp increase in earnings. For the Engineering segment, a slight rise in revenue is expected alongside a moderate increase in earnings; the record-high segment order book will only have an impact in the medium term (large-scale plant construction projects in the US). In Materials Solutions in particular, rising raw material prices (which are largely passed on to customers) play a key role in the expected moderate rise in revenue, although margins here will decline.
 
As rising raw material prices (particularly metals) will lead to higher working capital (inventories), free cash flow in 2026 is expected to be lower than in 2025. However, this challenge also presents an opportunity for INDUS, as smaller competitors unable to bear these costs could consequently exit the market.
 
Group outlook: For the 2026 financial year, INDUS is forecasting revenue of between €1.8 billion and €1.95 billion, with adjusted EBITA expected to be between €150 million and €170 million. This corresponds to an adjusted EBITA margin of between 7.5% and 9.5%. FCF is expected to exceed €70 million. 
 
DISCLAIMER
LEGAL NOTICE
 
This  research  report  ('Investment Recommendation') was prepared by Parmantier  & Cie. Research, 
with contributions from Mr. Grossjohann, and is distributed solely by Parmantier & Cie. Research.
It is intended only for the recipient and may not be shared with other entities, even if they are part
of the same  corporate  group, without  prior written consent. The  report contains  selected  information
and makes  no  claim  to  completeness.  The  investment  recommendation  is  based  on  publicly  available 
information  ('Information'), which  is  considered  correct and complete. However, Parmantier  & Cie. 
Research does not verify or guarantee the accuracy or completeness of this information. Any potential 
errors or omissions do not create liability for Parmantier & Cie. Research, which assumes no liability for 
direct, indirect, or consequential damages. 
 
In  particular,  Parmantier  &  Cie.  Research  accepts  no  responsibility  for  the  accuracy  of  statements, 
forecasts, or other content  in  this  investment  recommendation concerning  the analyzed companies, 
their  subsidiaries,  strategies,  economic  conditions,  market  and  competitive  positions,  regulatory 
frameworks, and similar factors. While care has been taken in preparing this report, errors or omissions 
cannot  be  excluded.  Parmantier  &  Cie.  Research,  including  its  partners  and employees,  accepts  no 
liability  for  the accuracy  or completeness  of  statements,  estimates,  or conclusions derived  from the 
provided information in this investment recommendation. 
 
To  the  extent  this  investment  recommendation  is  provided  as  part  of  an  existing  contractual 
relationship (e.g., financial advisory services), Parmantier & Cie. Research's liability is limited to cases of 
gross negligence or intentional misconduct. In cases of breach of essential obligations, liability is limited 
to simple negligence but is restricted to foreseeable and typical damages in all cases. This investment 
recommendation does not constitute an offer or solicitation to buy or sell securities. 
 
Partners, managing directors, or employees of Parmantier & Cie. Research or its subsidiaries may hold 
responsible positions, such as supervisory board mandates, in the companies mentioned in this report. 
The opinions expressed in this investment recommendation may change without notice and reflect the 
personal  view  of  the  research  analyst.  Unless  otherwise  stated,  no  part  of  the  research  analyst's 
compensation  is  directly  or  indirectly  related  to  the  recommendations  or opinions  contained  in  this 
report. All rights reserved.